Blue Trust Inc’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Blue Trust Inc’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-446	Closed	-$160	–	2906
2024 Q3	$160	Buy	+446	New	+$327	﹤0.01%	2869

Other funds holding SGMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Blue Trust Inc's SGMO Position: Q4 2024 in Review

Blue Trust Inc sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2024, closing a stake of 446 shares — an estimated $160 sold.

Blue Trust Inc first reported a position in SGMO in Q3 2024 and held it in 1 quarter. The position peaked at $160 in Q3 2024. 128 funds tracked by Wall St. Rank hold SGMO as of Q4 2024.

Blue Trust Inc reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2024 after selling out during the quarter.
Blue Trust Inc sold 446 SANGAMO THERAPEUTICS INC shares in Q4 2024, an estimated $160.
Blue Trust Inc first reported a position in SANGAMO THERAPEUTICS INC in Q3 2024 and held it in 1 quarter.
Blue Trust Inc's SANGAMO THERAPEUTICS INC position peaked at $160 in Q3 2024.
128 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2024.

Based on Blue Trust Inc's 13F filing for Q4 2024, filed 22 Jan 2025.